Singapore Clinical Trial: 'Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the post-operative survival of glaucoma drainage devices'

Singapore, Oct. 30 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the po... Read More

Singapore Clinical Trial: IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy.

Singapore, Oct. 30 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507... Read More

Singapore Clinical Trial: ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Singapore, Oct. 30 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemothera... Read More

Singapore Clinical Trial: ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Singapore, Oct. 30 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemothera... Read More

Singapore Clinical Trial: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

Singapore, Oct. 30 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safet... Read More

Singapore Clinical Trial: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy Versus Physician’s Choice of Chemotherapy in Participants With B7-H4-selected Advanced/Metastatic Endometrial Cancer Who Progressed on or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)

Singapore, Oct. 30 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) M... Read More

'Aswesuma' applicants not selected given opportunity to appeal

SriLanka, Oct. 30 -- The Welfare Benefits Board has announced that applicants who were found ineligible for the 'Aswesuma' welfare benefit scheme have been given an opportunity to submit appeals. Acc... Read More

Sanjivani Paranteral to conduct board meeting

Mumbai, Oct. 30 -- Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 5 November 2026. Published by HT Digital Content Services with permission from Capital Market.... Read More

Shriram Asset Mgt. Company to hold board meeting

Mumbai, Oct. 30 -- Shriram Asset Mgt. Company will hold a meeting of the Board of Directors of the Company on 5 November 2026. Published by HT Digital Content Services with permission from Capital Ma... Read More

Ecofinity Atomix to table results

Mumbai, Oct. 30 -- Ecofinity Atomix will hold a meeting of the Board of Directors of the Company on 7 November 2026. Published by HT Digital Content Services with permission from Capital Market.... Read More

• ««
• «
• 1304
• 1305
• 1306
• 1307
• 1308
• 1309
• 1310
• 1311
• 1312
• 1313
• »
• »»